Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Calcified hostile access can be an exclusion criteria for endograft delivery and has been associated with both perioperative and long term morbidity and mortality…this is changing! Join the discussion between Drs Bosiers, Fazzini and Isernia and hear how IVL is changing the boundaries in their daily practice for endograft delivery by changing vessel compliance, providing excellent luminal gain and improving patient safety, simplifying the challenges raised by hostile calcified access.
Topics: Peripheral IVL
Tune in for session 2 of Shockweek on Vascupedia as Dr. Elias Noory treats multiple highly calcified femoropopliteal lesions with IVL. During the session, our expert panel of Drs Lorenzo Patrone, Enrique Alejandre Lafont, Bella Huasen and Thanos Saratzis discuss how IVL can overcome the pitfalls of CLTI treatment by changing vessel compliance to reduce procedural complications. Dr. Noory and the panel also share pearls of wisdom on how to optimize your IVL strategy to get the best outcomes for patients and crack the calcium conundrum.
Topics: Peripheral IVL
Shockwave partnered with Vascupedia to host a week-long virtual event with live cases and panel discussions. Session one focuses on ‘A New Approach to Tackling Calcified Disease in Large Vessels’. In the session, Dr. Elias Noory presents a live case from Bad Krozingen, Germany and is accompanied by an esteemed panel of Drs Arko, Bisdas and Coscas who discuss the role of endovascular treatment for common femoral disease.
Tune in to hear from the experts on how IVL is changing the treatment paradigm for heavily calcified CFA disease by providing a safe and effective treatment for calcified vessels. See how Dr. Noory utilizes IVL to achieve increased vessel compliance and luminal gain to enable a ‘leave-nothing-behind’ strategy.
For the full video from Day 1 click here: https://vascupedia.com/presentation/a-new-approach-to-tackling-calcified-disease-in-large-vessels-shockweek-day-1/
Topics: Peripheral IVL
Just five years ago, we were a start-up, commencing the launch of our pioneering treatment for calcified cardiovascular disease. Today we are a public company with customers in over 60 countries and a robust pipeline of technologies in various stages of development. Backed by solid clinical results, our intravascular lithotripsy (IVL) system has been used to treat more than 120,000 patients worldwide and we have every reason to believe it will help millions.
Topics: IVL Technology, SWAV News
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
In a late-breaking clinical trial session at VIVA22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study (OS). PAD III OS represents the largest prospective ‘real-world’ evidence for the treatment of complex, heavily calcified peripheral artery disease. Building on the interim results presented at VIVA21, this larger patient data set reinforces the predictability of IVL and its ability to consistently modify calcium across vessel beds, challenging lesions, and complex patients (CLI, dialysis, and female patients). These real-world outcomes mirror the previously reported PAD III Randomized-Controlled Trial showing that IVL safely and effectively modifies challenging calcium in complex patients.
Check-out the presentation below and hear from Dr. Armstrong on the importance of the largest prospective ‘real-world’ data set in the treatment of heavily calcified PAD.
Topics: Peripheral IVL, Peripheral Conferences, Peripheral Clinical Data, Shockwave M5 & Shockwave M5+
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Female vs. Male Outcomes, Empower CAD
In this short video, Dr. Sundeep Kalra, Royal Free Hospital of London, UK, shares his experience with Shockwave IVL, highlighting his evolution in the use of the technology since he started in 2016. At that time, his main indication for use of IVL was severely calcified coronary arteries with > 270° arc of calcium on intravascular imaging. Nowadays, Dr. Kalra uses Shockwave IVL to treat the whole lesion throughout all calcium morphologies, to ensure good plaque modification and achieve greater stent expansion.
Here, Dr. Kalra presents one of his recent clinical cases with Shockwave IVL: a 77-year-old woman with worsening stable angina and severe calcified LAD. The patient was treated with a 3.0mm Shockwave C2, using 50 shocks to fracture nodular calcium and 30 shocks for the eccentric plaque, followed by stent placement.
Topics: Coronary IVL, Coronary Clinical Data, Shockwave C2
Join us in Las Vegas for VIVA 2022 as we crack into late breaking data supporting IVL’s consistency in calcium modification in real-world PAD. The late breaker, presented by Dr. Ehrin Armstrong, features the final 1,373 patient cohort datafrom the Disrupt PAD III Observational Study. Following the data release, an esteemed panel will discuss IVL’s consistent outcomes from both real-world AND randomized studies. Don’t roll the dice with calcium modification and join us at VIVA2022!
Topics: Peripheral IVL, IVL Technology, Peripheral Conferences, Peripheral Clinical Data
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
